Announcements Trials

Browse Landscape

Phase

Phase NA 2 Phase 1/2 1 Phase 1 1

Status

Completed 11 Terminated 4 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma in Situ 1

Interventions

Cyclophosphamide 35 Cisplatin 24 fludarabine 23 Radiotherapy 23 Paclitaxel 21 Carboplatin 20 pembrolizumab 18 Nivolumab 18 Magnetic Resonance Spectroscopy 18 Specimen Handling 17 fludarabine phosphate 15 Gemcitabine 15 Biopsy 15 Cytarabine 14 Radiation 11 Filgrastim 11 Doxorubicin 11 Docetaxel 11 Dexamethasone 11 Radiosurgery 10 Granulocyte Colony-Stimulating Factor 10 Etoposide 10 Melphalan 9 Ipilimumab 9 venetoclax 8 Rituximab 8 Calcium Dobesilate 8 trametinib 7 ibrutinib 7 durvalumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Withdrawn × 1-phenyl-3,3-dimethyltriazene × Clear all

NCT02698293 2022-11-22

PDT Plus Vitamin D3 for Anal Dysplasia

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn

Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon ⚡